[Br:1][CH2:2][C:3]([OH:5])=O.CC(N=C=NC(C)C)C.[NH2:15][C:16]1[CH:17]=[C:18]([S:22]([NH:25][C:26]2[C:35]([NH:36][C:37]3[CH:42]=[C:41]([O:43][CH3:44])[CH:40]=[C:39]([O:45][CH3:46])[CH:38]=3)=[N:34][C:33]3[C:28](=[CH:29][CH:30]=[CH:31][CH:32]=3)[N:27]=2)(=[O:24])=[O:23])[CH:19]=[CH:20][CH:21]=1>C(Cl)Cl>[Br:1][CH2:2][C:3]([NH:15][C:16]1[CH:21]=[CH:20][CH:19]=[C:18]([S:22](=[O:23])(=[O:24])[NH:25][C:26]2[C:35]([NH:36][C:37]3[CH:42]=[C:41]([O:43][CH3:44])[CH:40]=[C:39]([O:45][CH3:46])[CH:38]=3)=[N:34][C:33]3[C:28](=[CH:29][CH:30]=[CH:31][CH:32]=3)[N:27]=2)[CH:17]=1)=[O:5]In a 50 mL round-bottom flask was added 2-bromoacetic acid (1.87 g, 13.5 mmol), N,N-diisopropylcarbodiimide (860 mg, 6.8 mmol) and 10 mL DCM. To this mixture was added 3-amino-N-(3-(3,5-dimethoxyphenylamino) quinoxalin-2-yl)benzenesulfonamide (2.03 g, 4.5 mmol), prepared using procedures similar to those in Example 168. The reaction was stirred overnight at room temperature. Complete consumption of the starting aniline was confirmed by LCMS. The solvent was evaporated off to yield the crude product (2-bromo-N-(3-(N-(3-(3,5-dimethoxyphenylamino) quinoxalin-2-yl)sulfamoyl)phenyl)acetamide). This was used directly in the next step without further purification.